抗T2生物制剂对泼尼松依赖型哮喘患者肺通气MRI的影响
本研究对10例泼尼松依赖型哮喘伴未控制嗜酸性支气管炎患者进行吸入气体MRI,在加用抗T2治疗控制痰嗜酸性粒细胞后复查。
要点
- 抗T2治疗控制痰嗜酸性粒细胞后,MRI测得的通气缺陷百分比(VDP)在支气管舒张前后均改善。
- 基线痰嗜酸性粒细胞≥15.8%的患者支气管舒张后VDP改善更显著。
- 多数患者(7/10)在支气管舒张剂和抗T2治疗后仍存在残余通气缺陷。
核心结论
- 通过抗T2治疗控制痰嗜酸性粒细胞增多可改善泼尼松依赖型哮喘成人患者的MRI通气缺陷。
研究设计与样本
- 自身前后对照研究,纳入10例泼尼松依赖型哮喘伴未控制嗜酸性支气管炎(痰嗜酸性粒细胞≥3%)患者。
- 基线及558(100-995)天后(抗T2治疗控制嗜酸性支气管炎后)行吸入超极化气体MRI,支气管舒张前后评估VDP。
主要发现
- 10例患者中7例在支气管舒张剂和抗T2治疗后仍存在残余通气缺陷。
关键数值与推荐
- 抗T2治疗包括:美泊利单抗2例、瑞利珠单抗2例、贝那利珠单抗3例、度普利尤单抗1例、增加每日泼尼松2例。
- 嗜酸性支气管炎控制定义为痰嗜酸性粒细胞<3%。
临床怎么用
- 对于泼尼松依赖型哮喘伴嗜酸性支气管炎患者,抗T2治疗可改善区域通气,支持其用于控制嗜酸性气道炎症。
- MRI通气缺陷可作为评估抗T2治疗区域通气效果的影像学指标。
局限性
- 样本量小(10例),抗T2治疗方案异质(包括增加泼尼松),无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The functional consequence of airway obstruction in asthma can be regionally measured using inhaled gas MRI. Ventilation defects visualized by MRI persist post-bronchodilator in patients with severe asthma with uncontrolled sputum eosinophilia and may be due to eosinophil-driven airway pathology that is responsive to "anti-T2" therapy. RESEARCH QUESTION: Do anti-T2 therapies that clear eosinophils from the airway lumen decrease ventilation defects, measured by inhaled gas MRI, in adults with prednisone-dependent asthma? STUDY DESIGN AND METHODS: Inhaled hyperpolarized gas MRI was performed before and after bronchodilation in 10 prednisone-dependent patients with asthma with uncontrolled eosinophilic bronchitis (sputum eosinophils ≥3%) at baseline and 558 (100-995) days later when their eosinophilic bronchitis had been controlled (sputum eosinophils <3%) by additional anti-T2 therapy. The effect of anti-T2 therapy on ventilation defects, quantified as the MRI ventilation-defect-percent (VDP), was evaluated before and after bronchodilation for all patients and compared between patients dichotomized based on the median percentage of sputum eosinophils at baseline (15.8%). RESULTS: MRI VDP was improved pre- (ΔVDP+anti-T2: -3% ± 4%, P = .02) and post-bronchodilator (ΔVDP+anti-T2: -3% ± 4%; P = .04) after additional anti-T2 therapy that controlled eosinophilic bronchitis (n = 2 mepolizumab, n = 2 reslizumab, n = 3 benralizumab, n = 1 dupilumab, n = 2 increased daily prednisone). A greater post-bronchodilator ΔVDP+anti-T2 was observed in those patients with median or higher percentage of sputum eosinophils at baseline (≥15.8%; P = .01). In 7 of 10 patients with asthma, residual ventilation defects persisted despite bronchodilator and anti-T2 therapy. INTERPRETATION: Controlling sputum eosinophilia with anti-T2 therapies improves ventilation defects, measured by inhaled gas MRI, in adults with prednisone-dependent asthma.
引用
- Svenningsen S, Eddy RL, Kjarsgaard M, et al. Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma. Chest. 2020. PMID: 32428511. doi:10.1016/j.chest.2020.04.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。